The Trends that Shaped 2016: A Year in Review

2016 Trends in Pharma

The Trends that Shaped 2016: A Year in Review

If 2016 had an overriding theme it was one of instability. This sense of volatility manifested in a variety of ways from political clashes to Brexit, and the pharmaceutical industry was not immune. What remains constant is the industry’s focus on improving health outcomes for patients everywhere. Here are some of the year’s highlights:

Moving from Big Data to Actionable Analytics
The pharmaceutical industry is moving away from big data, turning instead to meaningful data that can lead to smarter decisions across the product development spectrum. As an Express Scripts company, UBC is tapping real-world data to help sponsors accelerate clinical trial enrollment. Manufacturers can also utilize this data to guide drug launch strategy and reveal patient and prescriber insights.

Unlocking a Faster Path to Therapy
For patients prescribed a specialty medication, wait time to initiate therapy could extend to days, weeks, or longer, depending on the level of administrative and financial hurdles the patient must overcome. To help patients access their medications as quickly as possible, UBC launched a new suite of digital tools to power the high-touch care our teams deliver. In the October issue of Pharmaceutical Executive, UBC’s top commercial strategy executive, Brett Huselton, dove deeper into the high-tech tools and high-touch methods used by UBC to unlock a faster path to therapy.

Welcoming the New Era of Patient Centricity
Patient-centricity was THE buzzword of the year, and for good reason. Focusing on the patient journey can accelerate enrollment in clinical trials and generate highly engaged patient populations, as we saw in Novartis’s PREFERMS study. This concept is also fueling the mHealth boom as sponsors seek ways to leverage real-time connectivity for their trials and eliminate barriers to participation.

As healthcare continues to compound with complexity, our Patient Access & Engagement team, led by PharmaVoice 100 recipient Nicole Hebbert, partners with pharma to develop programs that break down barriers with a “patient first” mentality. Nicole often reminds her team – and other leaders – that behind every phone call, fax, or email is a patient in need of care.

The Rise of Real-World Evidence
Real-world evidence is increasingly important for long-term product success. Post-approval research can be leveraged to craft a product’s unique value proposition, paving the way for increased market access. Our scientific experts have filled our library with free webinars and numerous abstracts that help sponsors understand and implement real-world evidence solutions for their products:

Personalized Medicine: The Future is Now
The industry is making huge strides towards personalized therapies that optimize patient outcomes and minimize adverse events. This is incredibly important in oncology where pharmacogenomics is shaping the landscape. Don Gabriel, MD, PhD, Sr. Director, Medical Oncology & Scientific Strategy, created an animated lesson and a deep dive into the impact of pharmacogenomics across the product lifecycle to educate and assist sponsors working in this critical disease state.

Building Trust & Engagement Starts with Nurses
At UBC, we know that trust and engagement are two ingredients needed to ensure clinical trials and breakthrough therapies are truly successful. This year, we showed how Nursing at UBC is changing the way care is delivered and impacting product performance and patient lives. If pharmaceutical sponsors and manufacturers want to build trust and engagement with patients and prescribers, they have to leverage someone they both rely on – Nurses.

We’re looking forward to the collaboration that will drive innovation in 2017. Connect with us on LinkedIn and Twitter or subscribe to the UBC blog to stay up to date on industry trends that emerge in the New Year.